Neurogene

NEUROGENE INC

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Cologne,,Germany,-,August,05,2024:,Foot,Locker,Logo,Over,A

News

Downgrades

Markets

Analyst Ratings

Trading Ideas

IOVA

NGNE

This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday

Germany,-,April,19,2024:,Coinbase,Mobile,Application,Running,On,Smartphone

Price Target

Pre-Market Outlook

ANNX

CAMT

COIN

ITOS

MGTX

ONON

WING

Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday

AFMD

BILL

INDI

MATX

NXRT

Stanley Black &amp; Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday

Neurogene Inc

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Neurogene Inc. - NGNE

Neurogene to Participate in Upcoming Conferences

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

Neurogene Announces Peer-Reviewed Publication Demonstrating Gene Therapy Candidate NGN-401 with EXACT™ Technology Regulates Transgene Expression in Preclinical Models of Rett Syndrome

Neurogene Announces Upcoming Oral Presentation on Monitoring and Treatment to Reverse Rare Complication of High Dose Gene Therapy at the ASGCT Annual Meeting

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Reports First Quarter 2025 Financial Results and Highlights Recent Updates

Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV

Allogene Therapeutics, Inc. - Common Stock

Allogene Therapeutics

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Annexon

Astria Therapeutics

Candel Therapeutics

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

Design Therapeutics

Foghorn Therapeutics

Monte Rosa Therapeutics, Inc. - Common Stock

Monte Rosa Therapeutics

Genfit

Gossamer Bio

Inozyme Pharma

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Monopar Therapeutics

Ocugen

Prothena Corporation plc - Ordinary Shares

Prothena Corp

Palvella Therapeutics, Inc. - Common Stock

Palvella Therapeutics

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Cartesian Therapeutics, Inc. - Common Stock

Cartesian Therapeutics

Solid Biosciences

Silence Therapeutics Plc - American Depository Share

Silence Therapeutics

Tango Therapeutics

Tonix Pharmaceuticals Holding Corp. - Common Stock

Tonix Pharmaceuticals

Tevogen Bio Holdings

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharmaceuticals

BMO Capital

Baird

HC Wainwright & Co.

Stifel

Comments

Neurogene

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell